San Francisco-based Dualitas Therapeutics has secured $65 million in a Series A funding round to develop bispecific antibodies that engage two targets on the same immune cell, enhancing immunomodulatory therapies for autoimmune and inflammatory conditions. Investors including Eli Lilly and Chugai Pharmaceutical back the startup’s proximity biology platform, positioning Dualitas at the forefront of next-generation immunotherapy innovation.